Merck & Co. Inc., known as MSD outside of the United States and Canada, has announced that Health Canada has approved KEYTRUDA® (pembrolizumab) for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer in combination with chemoradiotherapy $(CRT)$. This approval is based on the positive results from the Phase 3 KEYNOTE-A18/ENGOT-cx11/GOG-3047 trial, which demonstrated significant improvements in progression-free survival and overall survival for patients receiving the treatment compared to those receiving a placebo. This marks the first approval in Canada for KEYTRUDA® in combination with CRT, providing a vital new therapeutic option for patients battling this stage of cervical cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.